{
  "docId": "019de076-8e54-70f4-b1ec-6643014b872e",
  "docSlug": "869b7bb859e037e0c2aa4b6e5865c5ed",
  "documentTitle": "AbCellera | Investor Conference Presentation Deck | 14 slides",
  "authorId": "abcellera",
  "authorName": "AbCellera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 10,
  "pageCount": 14,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a two-column layout to present the value proposition of the platform.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-8e54-70f4-b1ec-6643014b872e/10",
  "deckHref": "/decks/019de076-8e54-70f4-b1ec-6643014b872e",
  "deckJsonHref": "/decks/019de076-8e54-70f4-b1ec-6643014b872e.json",
  "deckAnchorHref": "/decks/019de076-8e54-70f4-b1ec-6643014b872e#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.52,
        "y": 0.5
      },
      "kind": "callout",
      "text": "Expand the accessible target space for T-cell engagers in solid tumors by enabling discovery of antibodies that are highly specific to MHC-peptide complexes.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d0f6302-0ccd-4215-9c5d-57936e740497",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.09,
        "y": 0.5
      },
      "kind": "callout",
      "text": "Improve the safety profile of T-cell engagers by creating bispecific antibodies that achieve potent tumor killing with reduced cytokine release, which can help address dose-limiting toxicity.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ea3ce3b-816e-48a6-9452-3ffce674eaf1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.7,
        "x": 0.09,
        "y": 0.23
      },
      "kind": "paragraph",
      "text": "T-cell engagers have tremendous potential for the treatment of cancer and autoimmune conditions but are technically challenging to design and engineer. AbCellera’s T-cell engager platform combines unique discovery capabilities, bispecific engineering, and a panel of hundreds of diverse CD3-binding antibodies to potentially:",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0211cc7e-1420-4284-93b6-be896dba1895",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.82,
        "x": 0.09,
        "y": 0.14
      },
      "kind": "title",
      "text": "Continued progress and differentiation for T-cell engager platform.",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9dc08078-65e9-45fb-8a09-476a7c6bb255",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}